塩酸オキシブチニン(ポラキス錠)の臨床効果 - 特に,頻尿,尿意切迫感および尿失禁に対して -

Abstract

神経因性膀胱をはじめとして頻尿, 尿意切迫感および尿失禁を主訴とする患者を対象として塩酸オキシブチニンを投与し, 臨床症状を中心にその有効性, 安全性につき検討した.1)総症例数52例中44例が4週以上の投与を完了した.平均投与期間は66.8日であった.2)投与量別全般改善度を評価した成績は2 mg×3回群で"改善"以上の改善率は55%, "やや改善"以上が85%であり, 3 mg×3回群でそれぞれ68.2%, 95.5%であった.また1日2回投与でも臨床症状のコントロールが可能な症例を認めた.3)副作用は評価対象52例中2例に認められ, 2例とも口渇のみであり, 臨床上問題となる重篤なものはなかった.4)有用度は評価時において, "有用"以上67.3%, "やや有用"以上88.5%と高い有用率が得られた

The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence. Clinical responses to the drug were assessed mainly by the subjective symptoms of the patients. The diagnoses of these patients were neurogenic bladder in 17, unstable bladder in 16 and others in 19 patients. The average administration period was 66.8 days. The rate of global improvement (excellent and good) was 55% in the 2 mg dose given 3 times daily group, 68.2% in the 3 mg dose given 3 times daily group. Side effects, such as dry mouth, were observed in 2 of the 52 patients (3.8%), but no serious side effects were observed. The rate of global utility (remarkable and moderate) was 67.3%. These data indicate that oxybutynin hydrochloride seems to be useful and safe for the treatment of pollakisuria, urgency and urinary incontinence.